A study published in the BMJ investigated the possible effects of early initiation of prophylactic anticoagulation on risk of death among hospitalised COVID-19 patients in the United States. Results have shown that early initiation of prophylactic anticoagulation was "associated with a decreased risk of 30 day mortality and no increased risk of serious bleeding events." These findings suggests the use of prophylactic anticoagulation as treatment for hospitalised COVID-19 patients.